Monoclonal Antibody

单克隆抗体

• 批准号: 8933673
• 负责人: Frances Weis-Garcia
• 金额: $ 28.28万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8933673
• 关键词: Monoclonal; Antibody

The Monoclonal Antibody Core Facility (MACF) facilitates the acquisition and development of new antibodies for research studies by investigators in the Cancer Center. In some cases, antibodies are prepared in quantities and with purity suitable for in vivo preclinical studies. As such the MSCF is a vibrant and innovative core that contributes broadly to the basic and translational mission of the Center. Specifically the Core develops new MAbs/ hybridomas to a specific antigen of interest that work in the required application. The facility provides access to MAbs not otherwise readily available by: 1) Producing MAbs (in vitro); 2) Purifying MAbs; 3) Conjugating MAbs to fluorphores, proteins, Q dots; 3) Fragmenting MAbs into Fab and/or F(Ab')2 fragments. Cell cultures are a staple in cancer research and healthy cells are essential to acquiring solid and reproducable data from these in vitro systems. Since mycoplasmal contamination significantly alters cellular processes, routine testing is a good laboratory practice. To minimize problems from such contaminations the MACF also offers a mycoplasma testing service. The services provided by the Monoclonal Antibody Core have supported the research of 78 investigators in the past year. During the past grant period the work of the Core has contributed to 149 publications of researchers from 6 research programs, A recent paper from the laboratory Hans-Guido Wendel illustrates how the facility also meets novel requests. Wendel's work demonstrated that soluble Eph-receptor A7 suppresses tumor growth. This classification as a tumor suppressor is further supported by the fact that it Is lost in ~ 70% follicular lymphomas. The MACF contributed by purifying an anti-CD20-EPHA7 recombinant fusion antibody the Wendel group produced which had a therapeutic effect In tumor bearing mice. This customized chimeric protein was more effective than the parental CD20 antibody (Rituximab) at shrinking large tumors.

单克隆抗体核心设施（MACF）促进了新的 癌症中心的研究人员为研究提供抗体。在某些情况下，抗体是 以适合于体内临床前研究的量和纯度制备。因此，MSCF是一个充满活力的 和创新的核心，为中心的基本和翻译使命作出了广泛的贡献。具体 该中心针对感兴趣的特异性抗原开发了新的单克隆抗体/杂交瘤， 应用程序.该设施通过以下方式提供了获得MAb的途径：1）生产MAb（在培养基中）， 体外）; 2）纯化MAb; 3）将MAb缀合至荧光团、蛋白质、Q点; 3）将MAb片段化成 Fab和/或F（Ab '）2片段。细胞培养是癌症研究的主要内容，健康的细胞对癌症研究至关重要。 从这些体外系统中获得可靠和可再现的数据。由于支原体污染 显著改变细胞过程，常规检测是良好的实验室规范。尽量减少问题 MACF还提供支原体检测服务。提供的服务 在过去的一年里，单克隆抗体核心支持了78名研究人员的研究。在过去 赠款期间，核心的工作为来自6项研究的研究人员的149份出版物做出了贡献。 实验室Hans-Guido Wendel最近的一篇论文说明了该设施如何满足 新的要求。Wendel的工作表明可溶性Eh受体A7抑制肿瘤生长。这 作为肿瘤抑制因子的分类进一步得到以下事实的支持，即它在约70%的滤泡中丢失。 淋巴瘤MACF通过纯化抗CD 20-EPHA 7重组融合抗体， Wendel组对荷瘤小鼠有治疗作用。这种定制的嵌合体 蛋白质比亲本CD 20抗体（利妥昔单抗）在缩小大肿瘤方面更有效。